Literature DB >> 23585530

Krüppel-like factor 4 blocks tumor cell proliferation and promotes drug resistance in multiple myeloma.

Matthieu Schoenhals1, Alboukadel Kassambara, Jean-Luc Veyrune, Jerome Moreaux, Hartmut Goldschmidt, Dirk Hose, Bernard Klein.   

Abstract

Krüppel-like factor 4 is a transcription factor with anti-proliferative effects in differentiated cells, but with the ability to reprogram adult cells into cell-cycling pluripotent cells. In cancer, Krüppel-like factor 4 acts as either an anti-oncogene or an oncogene. We analyzed Krüppel-like factor 4 gene expression in multiple myeloma using Affymetrix microarrays. We generated conditionally expressing Krüppel-like factor 4 myeloma cell lines to investigate the function of this gene in myeloma biology. Krüppel-like factor 4 gene expression is high in normal plasma cells, but reduced in primary multiple myeloma cells from two-thirds of patients. It is not expressed by any human myeloma cell line due to promoter methylation. Conditional expression of Krüppel-like factor 4 led to complete cell cycle blockade, mainly in G1 phase, with no major apoptosis. This blockade was associated with induction of p21(Cip1) and p27(Kip1) in cell lines with an intact p53 pathway, and of p27(Kip1) only in those with an impaired p53 pathway. Krüppel-like factor 4 is highly expressed in the poor prognostic MS group with t(4;14) translocation and in the good prognostic CD-1 group with t(11;14) or t(6;14). The apparent contradiction of cell cycle inhibitor Krüppel-like factor 4 expression in patients with poor prognosis could be reconciled since its expression increased the resistance of myeloma cell lines to melphalan. In conclusion, we describe for the first time that Krüppel-like factor 4 could play a critical role in controlling the cell cycle and resistance to alkylating agents in multiple myeloma cells.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23585530      PMCID: PMC3762102          DOI: 10.3324/haematol.2012.066944

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  43 in total

1.  Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors.

Authors:  Z J Gu; J De Vos; C Rebouissou; M Jourdan; X G Zhang; J F Rossi; J Wijdenes; B Klein
Journal:  Leukemia       Date:  2000-01       Impact factor: 11.528

2.  Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma.

Authors:  X G Zhang; J P Gaillard; N Robillard; Z Y Lu; Z J Gu; M Jourdan; J M Boiron; R Bataille; B Klein
Journal:  Blood       Date:  1994-06-15       Impact factor: 22.113

3.  Cluster analysis and display of genome-wide expression patterns.

Authors:  M B Eisen; P T Spellman; P O Brown; D Botstein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-08       Impact factor: 11.205

4.  Identification of Krüppel-like factor 4 as a potential tumor suppressor gene in colorectal cancer.

Authors:  Weidong Zhao; Irfan M Hisamuddin; Mandayam O Nandan; Brian A Babbin; Neil E Lamb; Vincent W Yang
Journal:  Oncogene       Date:  2004-01-15       Impact factor: 9.867

5.  A gp130 interleukin-6 transducer-dependent SCID model of human multiple myeloma.

Authors:  C Rebouissou; J Wijdenes; P Autissier; K Tarte; V Costes; J Liautard; J F Rossi; J Brochier; B Klein
Journal:  Blood       Date:  1998-06-15       Impact factor: 22.113

6.  Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays.

Authors:  John De Vos; Thomas Thykjaer; Karin Tarte; Matthias Ensslen; Pierre Raynaud; Guilhem Requirand; Florence Pellet; Véronique Pantesco; Thierry Rème; Michel Jourdan; Jean-François Rossi; Torben Ørntoft; Bernard Klein
Journal:  Oncogene       Date:  2002-10-03       Impact factor: 9.867

7.  Downregulation and growth inhibitory effect of epithelial-type Krüppel-like transcription factor KLF4, but not KLF5, in bladder cancer.

Authors:  Shunsuke Ohnishi; Sumiko Ohnami; Friedrich Laub; Kazunori Aoki; Koichi Suzuki; Yae Kanai; Kazunori Haga; Masahiro Asaka; Francesco Ramirez; Teruhiko Yoshida
Journal:  Biochem Biophys Res Commun       Date:  2003-08-22       Impact factor: 3.575

8.  The zinc-finger transcription factor Klf4 is required for terminal differentiation of goblet cells in the colon.

Authors:  Jonathan P Katz; Nathalie Perreault; Bree G Goldstein; Catherine S Lee; Patricia A Labosky; Vincent W Yang; Klaus H Kaestner
Journal:  Development       Date:  2002-06       Impact factor: 6.868

Review 9.  Statistical tests for differential expression in cDNA microarray experiments.

Authors:  Xiangqin Cui; Gary A Churchill
Journal:  Genome Biol       Date:  2003-03-17       Impact factor: 13.583

10.  Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer.

Authors:  Irfan A Asangani; Bushra Ateeq; Qi Cao; Lois Dodson; Mithil Pandhi; Lakshmi P Kunju; Rohit Mehra; Robert J Lonigro; Javed Siddiqui; Nallasivam Palanisamy; Yi-Mi Wu; Xuhong Cao; Jung H Kim; Meng Zhao; Zhaohui S Qin; Mathew K Iyer; Christopher A Maher; Chandan Kumar-Sinha; Sooryanarayana Varambally; Arul M Chinnaiyan
Journal:  Mol Cell       Date:  2012-11-15       Impact factor: 17.970

View more
  18 in total

Review 1.  Novel tumor-suppressor function of KLF4 in pediatric T-cell acute lymphoblastic leukemia.

Authors:  Ye Shen; Taylor J Chen; H Daniel Lacorazza
Journal:  Exp Hematol       Date:  2017-05-04       Impact factor: 3.084

2.  IL-6 supports the generation of human long-lived plasma cells in combination with either APRIL or stromal cell-soluble factors.

Authors:  M Jourdan; M Cren; N Robert; K Bolloré; T Fest; C Duperray; F Guilloton; D Hose; K Tarte; B Klein
Journal:  Leukemia       Date:  2014-02-07       Impact factor: 11.528

3.  KLF4: A new player in plasma cell development.

Authors:  Olivier Elemento
Journal:  Cell Cycle       Date:  2016-08-02       Impact factor: 4.534

4.  Forced KLF4 expression increases the generation of mature plasma cells and uncovers a network linked with plasma cell stage.

Authors:  Matthieu Schoenhals; Michel Jourdan; Anja Seckinger; Véronique Pantesco; Dirk Hose; Alboukadel Kassambara; Jérôme Moreaux; Bernard Klein
Journal:  Cell Cycle       Date:  2016-05-26       Impact factor: 4.534

5.  Metabolic, Anti-apoptotic and Immune Evasion Strategies of Primary Human Myeloma Cells Indicate Adaptations to Hypoxia.

Authors:  Lukas Janker; Rupert L Mayer; Andrea Bileck; Dominique Kreutz; Johanna C Mader; Kirsten Utpatel; Daniel Heudobler; Hermine Agis; Christopher Gerner; Astrid Slany
Journal:  Mol Cell Proteomics       Date:  2019-02-21       Impact factor: 5.911

6.  Germline Lysine-Specific Demethylase 1 (LSD1/KDM1A) Mutations Confer Susceptibility to Multiple Myeloma.

Authors:  Xiaomu Wei; M Nieves Calvo-Vidal; Siwei Chen; Gang Wu; Maria V Revuelta; Jian Sun; Jinghui Zhang; Michael F Walsh; Kim E Nichols; Vijai Joseph; Carrie Snyder; Celine M Vachon; James D McKay; Shu-Ping Wang; David S Jayabalan; Lauren M Jacobs; Dina Becirovic; Rosalie G Waller; Mykyta Artomov; Agnes Viale; Jayeshkumar Patel; Jude Phillip; Selina Chen-Kiang; Karen Curtin; Mohamed Salama; Djordje Atanackovic; Ruben Niesvizky; Ola Landgren; Susan L Slager; Lucy A Godley; Jane Churpek; Judy E Garber; Kenneth C Anderson; Mark J Daly; Robert G Roeder; Charles Dumontet; Henry T Lynch; Charles G Mullighan; Nicola J Camp; Kenneth Offit; Robert J Klein; Haiyuan Yu; Leandro Cerchietti; Steven M Lipkin
Journal:  Cancer Res       Date:  2018-03-20       Impact factor: 12.701

7.  Phase 1 study of APTO-253 HCl, an inducer of KLF4, in patients with advanced or metastatic solid tumors.

Authors:  Andrea Cercek; Jennifer Wheler; Peter E Murray; Shawn Zhou; Leonard Saltz
Journal:  Invest New Drugs       Date:  2015-08-14       Impact factor: 3.850

8.  Inactivation of KLF4 promotes T-cell acute lymphoblastic leukemia and activates the MAP2K7 pathway.

Authors:  Y Shen; C S Park; K Suppipat; T-A Mistretta; M Puppi; T M Horton; K Rabin; N S Gray; J P P Meijerink; H D Lacorazza
Journal:  Leukemia       Date:  2016-11-22       Impact factor: 12.883

9.  A KLF4-DYRK2-mediated pathway regulating self-renewal in CML stem cells.

Authors:  Chun Shik Park; Andrew H Lewis; Taylor J Chen; Cory S Bridges; Ye Shen; Koramit Suppipat; Monica Puppi; Julie A Tomolonis; Paul D Pang; Toni-Ann Mistretta; Leyuan Ma; Michael R Green; Rachel Rau; H Daniel Lacorazza
Journal:  Blood       Date:  2019-11-28       Impact factor: 25.476

10.  KLF4-SQSTM1/p62-associated prosurvival autophagy contributes to carfilzomib resistance in multiple myeloma models.

Authors:  Irene Riz; Teresa S Hawley; Robert G Hawley
Journal:  Oncotarget       Date:  2015-06-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.